View Older Stories View More Recent Stories

May 21, 2026 06:00PM OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 19, 2026 04:05PM Veracyte to Participate in Upcoming Investor Conferences
May 15, 2026 09:00AM Veracyte receives Medicare coverage for bladder cancer monitoring test
May 15, 2026 09:00AM Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 5, 2026 04:05PM Veracyte Announces First Quarter 2026 Financial Results
Apr 28, 2026 09:00AM Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Apr 14, 2026 04:05PM Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
Mar 16, 2026 04:15PM Veracyte appoints Kevin Haas as chief development and technology officer
Mar 16, 2026 04:15PM Veracyte Names Kevin Haas as Chief Development and Technology Officer
Feb 25, 2026 04:05PM Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
Feb 24, 2026 09:00AM Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
Feb 19, 2026 05:00PM Veracyte to Participate in Upcoming Investor Conferences
Feb 4, 2026 05:15PM Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Jan 11, 2026 04:30PM Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Dec 29, 2025 04:30PM Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nov 6, 2025 08:30AM Veracyte to Participate in Upcoming Investor Conferences
Nov 4, 2025 04:05PM Veracyte Announces Third Quarter 2025 Financial Results
Nov 3, 2025 04:15PM Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
Oct 15, 2025 05:31PM Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
Sep 29, 2025 04:36AM Veracyte biomarker predicts hormone therapy benefit in prostate cancer
Sep 28, 2025 04:00PM Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
Sep 24, 2025 09:03AM Veracyte to present prostate cancer biomarker data at ASTRO 2025
Sep 24, 2025 09:00AM Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
Sep 9, 2025 09:00AM Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
Aug 29, 2025 08:30AM Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 27, 2025 11:25AM Veracyte study shows Decipher test predicts chemotherapy benefit
Aug 27, 2025 11:25AM Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Aug 26, 2025 08:35AM Veracyte completes enrollment for lung cancer test clinical trial
Aug 26, 2025 08:30AM Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
Aug 6, 2025 04:05PM Veracyte Announces Second Quarter 2025 Financial Results
Jul 17, 2025 05:30PM Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
Jul 8, 2025 04:05PM Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
May 28, 2025 04:05PM Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
May 20, 2025 05:00PM Veracyte to Participate in Upcoming Investor Conferences
May 7, 2025 04:05PM Veracyte Announces First Quarter 2025 Financial Results
Apr 25, 2025 07:00AM Veracyte (VCYT) Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Apr 25, 2025 07:00AM Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Apr 22, 2025 09:00AM Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
Apr 21, 2025 04:07PM Veracyte (VCYT) Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
Apr 21, 2025 04:05PM Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
Apr 16, 2025 06:30PM Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Mar 25, 2025 04:05PM New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
Mar 19, 2025 05:00PM Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
Feb 24, 2025 04:05PM Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
Feb 19, 2025 05:05PM Veracyte to Participate in Upcoming Investor Conferences
Feb 14, 2025 08:30AM New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Feb 11, 2025 08:30AM Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Feb 5, 2025 08:30AM New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Feb 4, 2025 04:30PM Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
Dec 5, 2024 04:05PM Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
View More Recent Stories View Older Stories